Navigation Links
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Date:11/6/2008

ialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, the efficacy of PROVENGE or sipuleucel-T, the company's lead product candidate to treat men suffering from prostate cancer, the efficacy of NEUVENGE or lapuleucel-T, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE or NEUVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the results of a clinical trial for PROVENGE, NEUVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015 Legal-Bay LLC, The Lawsuit ... Joseph Goodwin in the Southern District of ... transvaginal mesh cases against Ethicon for a single trial ... cases for the 26 women include claims from the ... made my Johnson & Johnson,s Ethicon subsidiary. The cases ...
(Date:7/1/2015)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... the Cantor Fitzgerald Healthcare Conference in New York ... Cox , executive vice president and chief operating officer, will ... financial update on Wednesday, July 8, 2015 at 9:30 a.m. ... audio webcast of the presentation may be accessed from the ...
(Date:7/1/2015)... 2015 Research ... addition of the "2015 New Frontiers ... Business Challenges, Emerging Technologies, Competitive Landscape" ... New Frontiers in European Clinical Chemistry and ... Landscape is a new five-country strategic analysis ...
Breaking Medicine Technology:Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 22015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 2
... USANA Health Sciences, Inc. (NYSE: ... are common in the average American diet and that dietary ...  However, USANA scientists and advising physicians caution that many important ... Dietary Guidelines for Americans, 2010 and that the ...
... 10, 2011 For the biopharmaceutical industry, the ... and difficulty - of interacting with patients to ... created both opportunities and challenges for approaching and ... To help marketing teams in the biopharmaceutical ...
Cached Medicine Technology:USDA Recognizes Benefit of Supplements in New Dietary Guidelines But Doesn't Go Far Enough 2Innovations in Patient-Focused Initiatives to Improve Outcomes 2
(Date:7/2/2015)... ... , ... ActiveBunch.com recently launched as a social network created for people with ... lifestyle community, Active Bunch allows users to connect with like-minded fitness enthusiasts from around ... or group events. , The spokesperson for Active Bunch explained the idea behind ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... with care and precision. There is an art and science that goes into ... of successfully reshaping the facial features and lives of more than 2,500 satisfied ...
(Date:7/2/2015)... ... July 02, 2015 , ... Five individuals from ... in Anniston for specialized disaster training. The team – composed of four clinicians ... California Hospital Association who attended the training, which is dedicated to preparing first ...
(Date:7/2/2015)... ... , ... After conducting a nationwide executive search led by healthcare ... Ariz., has hired Robert Trenschel, DO, as chief executive officer. A veteran physician executive ... his new duties at Yuma Regional Medical Center on July 13. , “Dr. Trenschel ...
(Date:7/2/2015)... ... 02, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that it has made two key appointments at its ... Manager at Catalent’s Schorndorf facility, which provides large scale, complex oral solid manufacturing ...
Breaking Medicine News(10 mins):Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 2Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 3Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2
... from product design and development through ... ... a,leading product design and development company, announced today that it has,received ... Services, Division of Food, Drug and Radiation Safety to,manufacture class I ...
... is the first Southern-style canned product ... by the American Heart Association, COLUMBUS, Ohio, Jan. ... lower sodium, low fat and meatless, were the first,product ... maintaining a savory,taste. Now, heart-healthy Sensibly Seasoned products also ...
... HARRISBURG, Pa., Jan. 9 Consumption of,sugary beverages can ... know that,some soft drinks contain as much as 11 ... also contain phosphoric and citric acids? Prolonged,exposure to these ... from the,tooth surface., According to Dr. Bruce Terry, ...
... Georgia Locations, ATLANTA, Jan. 9 Georgia Cancer Specialists ... -- will team,up with WSB-TV for the sixth annual "Totes ... GCS offices across Georgia on Friday, January 18,2008, from 10 ... or nearly new suitcases to foster children,in Georgia, many of ...
... say , , WEDNESDAY, Jan. 9 (HealthDay News) -- Researchers ... acid (RNA) molecules that seem to control whether or ... , These "microRNAs" essentially serve as brakes on the ... the disease to spread freely. When they are restored, ...
... WEDNESDAY, Jan. 9 (HealthDay News) -- Two new studies ... wisdom of treating with corticosteroids, intensive insulin therapy or ... , The first study compared the use of hydrocortisone ... found no improvement in survival rates. , The second ...
Cached Medicine News:Health News:Hiemstra Approved to Manufacture Medical Devices in New CER 2Health News:Glory Foods Receives Heart Healthy Certification 2Health News:Keep a Watchful Eye on Sugary Beverage Consumption 2Health News:Georgia Cancer Specialists to Sponsor Sixth Annual 'Totes 2 Tots' Suitcase Drive for Foster Children 2Health News:Georgia Cancer Specialists to Sponsor Sixth Annual 'Totes 2 Tots' Suitcase Drive for Foster Children 3Health News:Tiny RNA Molecules Control Breast Cancer's Spread 2Health News:Tiny RNA Molecules Control Breast Cancer's Spread 3Health News:Tiny RNA Molecules Control Breast Cancer's Spread 4Health News:Standard Septic Shock Treatments Ineffective 2Health News:Standard Septic Shock Treatments Ineffective 3Health News:Standard Septic Shock Treatments Ineffective 4
... Opmi Vario/NC33 system microscope provides surgeons ... pathology. These microscopes are ideal for many ... compact. Ergonomically designed at every point of ... utilized in a surgical microscope allows intuitive ...
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
26 cm - 10 1/4, 140 mm - 5 1/2, bayonet-shaped, flexible, 90 angle, 4 mm...
Toothed pituitary rongeur....
Medicine Products: